Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Full regeneration of maxillary alveolar bone using autogenous partially demineralized dentin matrix and PCBM for implant-supported full arch rehabilitation.

Umebayashi M, Ohba S, Kurogi T, Noda S, Asahina I.

J Oral Implantol. 2020 Jan 7. doi: 10.1563/aaid-joi-D-19-00315. [Epub ahead of print]

PMID:
31910061
2.

Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy.

Oyama Y, Onishi H, Koga S, Murahashi M, Ichimiya S, Nakayama K, Fujimura A, Kawamoto M, Imaizumi A, Umebayashi M, Ohuchida K, Morisaki T, Nakamura M.

J Immunother. 2019 Dec 4. doi: 10.1097/CJI.0000000000000305. [Epub ahead of print]

PMID:
31834207
3.

PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.

Fujimura A, Nakayama K, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Umebayashi M, Koya N, Morisaki T, Nakagawa T, Onishi H.

Cancer Immunol Immunother. 2019 Oct;68(10):1649-1660. doi: 10.1007/s00262-019-02403-y. Epub 2019 Sep 27.

PMID:
31562536
4.

Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy.

Morisaki T, Kubo M, Umebayashi M, Yuan Y, Tsuyada A, Tanaka H, Koya N, Nakagawa S, Morisaki T, Nakamura M.

Anticancer Res. 2019 Aug;39(8):4517-4523. doi: 10.21873/anticanres.13628.

PMID:
31366554
5.

Liprin-α4 as a New Therapeutic Target for SCLC as an Upstream Mediator of HIF1α.

Onishi H, Yamasaki A, Nakamura K, Ichimiya S, Yanai K, Umebayashi M, Nagai S, Morisaki T.

Anticancer Res. 2019 Mar;39(3):1179-1184. doi: 10.21873/anticanres.13227.

PMID:
30842147
6.

Combination of polyetherketoneketone scaffold and human mesenchymal stem cells from temporomandibular joint synovial fluid enhances bone regeneration.

Lin Y, Umebayashi M, Abdallah MN, Dong G, Roskies MG, Zhao YF, Murshed M, Zhang Z, Tran SD.

Sci Rep. 2019 Jan 24;9(1):472. doi: 10.1038/s41598-018-36778-2.

7.

A Chemogenetic Approach for the Optical Monitoring of Voltage in Neurons.

Sundukova M, Prifti E, Bucci A, Kirillova K, Serrao J, Reymond L, Umebayashi M, Hovius R, Riezman H, Johnsson K, Heppenstall PA.

Angew Chem Int Ed Engl. 2019 Feb 18;58(8):2341-2344. doi: 10.1002/anie.201812967. Epub 2019 Jan 25.

8.

RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.

Onishi H, Ichimiya S, Yanai K, Umebayashi M, Nakamura K, Yamasaki A, Imaizumi A, Nagai S, Murahashi M, Ogata H, Morisaki T.

Anticancer Res. 2018 Aug;38(8):4543-4547. doi: 10.21873/anticanres.12758.

PMID:
30061220
9.

Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.

Kubo M, Umebayashi M, Kurata K, Mori H, Kai M, Onishi H, Katano M, Nakamura M, Morisaki T.

Anticancer Res. 2018 Jul;38(7):4273-4279. doi: 10.21873/anticanres.12724.

PMID:
29970561
10.

Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.

Kawamoto M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Kawabe K, Onishi H, Nakamura M, Morisaki T.

Anticancer Res. 2018 May;38(5):2739-2748.

PMID:
29715094
11.

Clinical application of autogenous partially demineralized dentin matrix prepared immediately after extraction for alveolar bone regeneration in implant dentistry: a pilot study.

Minamizato T, Koga T, I T, Nakatani Y, Umebayashi M, Sumita Y, Ikeda T, Asahina I.

Int J Oral Maxillofac Surg. 2018 Jan;47(1):125-132. doi: 10.1016/j.ijom.2017.02.1279. Epub 2017 Aug 10.

PMID:
28802762
12.

Hedgehog signaling regulates PDL-1 expression in cancer cells to induce anti-tumor activity by activated lymphocytes.

Onishi H, Fujimura A, Oyama Y, Yamasaki A, Imaizumi A, Kawamoto M, Katano M, Umebayashi M, Morisaki T.

Cell Immunol. 2016 Dec;310:199-204. doi: 10.1016/j.cellimm.2016.08.003. Epub 2016 Aug 8.

PMID:
27522179
13.

Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.

Luo H, Umebayashi M, Doi K, Morisaki T, Shirasawa S, Tsunoda T.

Anticancer Res. 2016 Jul;36(7):3585-9.

PMID:
27354627
14.

Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line.

Imaizumi A, Onishi H, Yamasaki A, Kawamoto M, Umebayashi M, Morisaki T, Hasumi K.

Anticancer Res. 2016 Feb;36(2):653-7.

PMID:
26851020
15.

CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells.

Suyama K, Onishi H, Imaizumi A, Shinkai K, Umebayashi M, Kubo M, Mizuuchi Y, Oda Y, Tanaka M, Nakamura M, Katano M.

Cancer Lett. 2016 Apr 28;374(1):44-53. doi: 10.1016/j.canlet.2015.12.013. Epub 2016 Jan 12.

PMID:
26797459
16.

Onlay bone augmentation on mouse calvarial bone using a hydroxyapatite/collagen composite material with total blood or platelet-rich plasma.

Ohba S, Sumita Y, Umebayashi M, Yoshimura H, Yoshida H, Matsuda S, Kimura H, Asahina I, Sano K.

Arch Oral Biol. 2016 Jan;61:23-7. doi: 10.1016/j.archoralbio.2015.10.012. Epub 2015 Oct 22.

PMID:
26492524
17.

Gene-Activated Matrix Comprised of Atelocollagen and Plasmid DNA Encoding BMP4 or Runx2 Promotes Rat Cranial Bone Augmentation.

Umebayashi M, Sumita Y, Kawai Y, Watanabe S, Asahina I.

Biores Open Access. 2015 Feb 1;4(1):164-74. doi: 10.1089/biores.2014.0057. eCollection 2015.

18.

NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.

Morisaki T, Hirano T, Koya N, Kiyota A, Tanaka H, Umebayashi M, Onishi H, Katano M.

Anticancer Res. 2014 Aug;34(8):4529-38. Erratum in: Anticancer Res. 2014 Sep;34(9):5227.

PMID:
25075096
19.

An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.

Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M, Morisaki T.

Anticancer Res. 2014 Aug;34(8):4509-19.

PMID:
25075094
20.

Random migration contributes to cytotoxicity of activated CD8+ T-lymphocytes but not NK cells.

Onishi H, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M, Morisaki T.

Anticancer Res. 2014 Aug;34(8):3947-56.

PMID:
25075016

Supplemental Content

Loading ...
Support Center